BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23475758)

  • 1. Current approaches for the treatment of multiple myeloma.
    Watanabe R; Tokuhira M; Kizaki M
    Int J Hematol; 2013 Mar; 97(3):333-44. PubMed ID: 23475758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
    McCarthy PL; Einsele H; Attal M; Giralt S
    Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy for multiple myeloma.
    McCarthy PL; Palumbo A
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):839-59. PubMed ID: 25212886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple myeloma: an emphasis on new developments.
    Kyle RA; Vincent Rajkumar S
    Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
    Barlogie B
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latest advances and current challenges in the treatment of multiple myeloma.
    Mahindra A; Laubach J; Raje N; Munshi N; Richardson PG; Anderson K
    Nat Rev Clin Oncol; 2012 Feb; 9(3):135-43. PubMed ID: 22349016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments for myeloma.
    Azaïs I; Brault R; Debiais F
    Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
    Lee HS; Min CK
    Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
    Gertz MA; Kumar S; Lacy MQ; Dispenzieri A; Dingli D; Hayman SR; Buadi FK; Hogan WJ
    Blood; 2010 Mar; 115(12):2348-53; quiz 2560. PubMed ID: 20089967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloma: making sense of a complex blood cancer.
    Kelly MB; Meenaghan T; Dowling M
    Br J Nurs; 2010 Dec 9-2011 Jan 13; 19(22):1415-21. PubMed ID: 21139523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat high-risk myeloma.
    Lonial S; Boise LH; Kaufman J
    Blood; 2015 Sep; 126(13):1536-43. PubMed ID: 26272217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
    Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
    Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies for the treatment of multiple myeloma.
    Saini N; Mahindra A
    Discov Med; 2013 Apr; 15(83):251-8. PubMed ID: 23636142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
    Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
    Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in post-transplant maintenance treatment of multiple myeloma.
    Liu H; McCarthy P
    Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.